339.66
-11.04 (-3.15%)
Penutupan Terdahulu | 350.70 |
Buka | 357.81 |
Jumlah Dagangan | 329,131 |
Purata Dagangan (3B) | 345,684 |
Modal Pasaran | 7,408,120,320 |
Harga / Jualan (P/S) | 91.48 |
Harga / Buku (P/B) | 9.51 |
Julat 52 Minggu | |
Tarikh Pendapatan | 31 Oct 2024 |
Margin Operasi (TTM) | -187.06% |
EPS Cair (TTM) | -25.05 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 15.33% |
Nisbah Semasa (MRQ) | 5.98 |
Aliran Tunai Operasi (OCF TTM) | -431.02 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -263.11 M |
Pulangan Atas Aset (ROA TTM) | -52.25% |
Pulangan Atas Ekuiti (ROE TTM) | -129.76% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Madrigal Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -3.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.0 |
Purata | 0.75 |
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 8.56% |
% Dimiliki oleh Institusi | 105.84% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 441.00 (UBS, 29.84%) | Beli |
Median | 400.00 (17.77%) | |
Rendah | 236.00 (B. Riley Securities, -30.52%) | Pegang |
Purata | 370.80 (9.17%) | |
Jumlah | 4 Beli, 1 Pegang | |
Harga Purata @ Panggilan | 300.46 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 14 Jan 2025 | 400.00 (17.76%) | Beli | 303.71 |
22 Oct 2024 | 390.00 (14.82%) | Beli | 203.59 | |
JMP Securities | 10 Jan 2025 | 427.00 (25.71%) | Beli | 338.91 |
B. Riley Securities | 05 Nov 2024 | 236.00 (-30.52%) | Pegang | 337.61 |
UBS | 01 Nov 2024 | 441.00 (29.84%) | Beli | 319.58 |
Oppenheimer | 23 Oct 2024 | 350.00 (3.04%) | Beli | 202.48 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |